title: [Advances in the medical treatment of bacterial endophthalmitis].
abstract: Currently, the systemic antibiotics intraocular penetration's rate is low and we have to perform intraocular antibiotics injections to reach levels above the minimal inhibitory concentration of the bacterial agents found commonly in endophthalmitis. Authors try to specify a rational strategy based on pharmacokinetics and bacteriological aspects of a new class of antibiotics, the fluoroquinolones, using their own studies and those from other teams about the intraocular distribution of these antibiotics. Further investigation is mandatory to assess the safety and efficacy of our first clinical results.
authors.forename: A
authors.initials: A
authors.lastname: Bron
authors.forename: D
authors.initials: D
authors.lastname: Talon
authors.forename: J M
authors.initials: JM
authors.lastname: Estavoyer
authors.forename: B
authors.initials: B
authors.lastname: Delbosc
authors.forename: M
authors.initials: M
authors.lastname: Montard
authors.forename: J
authors.initials: J
authors.lastname: Royer
mesh_terms: D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications*; D002985:Clinical Protocols / Q000592:standards; D009877:Endophthalmitis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006801:Humans
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents
vernacular_title: Les progrès du traitement médical des endophtalmies bactériennes.